Syndax describes the drug as the first of its kind.
FDA Approves Revuforj to Treat R/R Acute Leukemia with KMT2A Translocation
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours